Immune checkpoint-related gene polymorphisms are associated with acute myeloid leukemia

Background: Chemotherapy is still the standard regimen for treating acute myeloid leukemia (AML) and its disappointing efficacy requires the urgent need for new therapeutic targets. It is well known that immune response plays an increasingly significant role in the pathogenesis of AML.Methods: We detected nine single nucleotide polymorphisms (SNPs) in immune checkpoint-related genes, including PD1, LAG3, TIM3, and TIGIT in 285 AML inpatients and 324 healthy controls. SNP genotyping was performed on the MassARRAY platform. Furthermore, we analyzed the relationship between the susceptibility and prognosis of AML and the selected SNPs.Results: Our results showed that rs2227982 and rs10204525 in PD1 were significantly associated with susceptibility to AML after false discovery rate correction. PD1 rs10204525 also showed a significant correlation with the response to chemotherapy and risk stratification of AML. Importantly, the AA genotype of PD1 (rs2227982) under the recessive model showed a negative impact on AML prognosis independently.Conclusions: Our results indicate that PD1 SNPs are important for susceptibility and prognosis in AML, which may provide a new therapeutic target for AML patients.

Automated summary

Chemotherapy is the standard treatment for acute myeloid leukemia (AML), but its efficacy is disappointing, highlighting the need for new therapeutic targets. This study found that certain single nucleotide polymorphisms (SNPs) in the PD1 gene are associated with susceptibility and prognosis of AML, suggesting a potential new therapeutic target for AML patients.